How should calcium polystyrene sulphonate be used, dosed, and monitored for treating hyperkalaemia, especially in patients with renal impairment?

Calcium Polystyrene Sulphonate: Use with Extreme Caution or Avoid Entirely

Given the serious safety concerns, lack of robust efficacy data, and availability of safer alternatives, calcium polystyrene sulphonate should generally be avoided in favor of newer potassium binders (patiromer or sodium zirconium cyclosilicate) for treating hyperkalaemia, particularly for chronic management.

Critical Safety Concerns

The polystyrene sulphonate class (both sodium and calcium formulations) carries significant morbidity and mortality risks that must be prioritized:

• Fatal gastrointestinal complications including intestinal necrosis, ischemic colitis, perforation, and bleeding have been reported, with an overall mortality rate of 33% in some series 1
• The FDA label carries explicit warnings about cases of fatal GI injury 2
• Risk factors include renal insufficiency, bowel disease history, post-surgical states, hypovolemia, and constipation 2

Contraindications (absolute):

• Obstructive bowel disease
• Patients without normal bowel function or recent post-operative period
• History of bowel impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, or previous bowel resection 2

Dosing (If No Alternative Available)

While I strongly recommend newer agents, if calcium polystyrene sulphonate must be used:

Oral administration:

• 15g orally 1-4 times daily (typical range 15-60g/day total)
• Suspend in 3-4 mL water or syrup per gram of resin
• Administer with patient upright to prevent aspiration 2
• Separate from other oral medications by at least 3 hours (6 hours if gastroparesis) 2

Rectal administration:

• 30-50g every 6 hours as retention enema
• Retain as long as possible, follow with non-sodium cleansing enema 2

Efficacy Limitations

The evidence base for calcium polystyrene sulphonate is remarkably weak:

• Only one small 7-day randomized trial (N=33) supports its use 1
• Onset of action is variable (hours to days), making it unsuitable for acute life-threatening hyperkalaemia 1
• Short-term efficacy is inconsistent 1

Recent studies show modest potassium reduction (0.64-0.94 mmol/L decrease over 7 days with 15-30g daily doses) 3, but this is inferior to newer agents.

Monitoring Requirements

Essential monitoring during therapy:

• Serum potassium (risk of severe hypokalaemia)
• Serum calcium and magnesium (nonselective binding causes depletion) 2
• Bowel function daily (discontinue immediately if constipation develops) 2
• Signs of fluid overload if using sodium formulation

For chronic hyperkalaemia, once potassium normalizes with appropriate therapy, resume standard monitoring per underlying condition (2-4 times yearly for CKD/HF/diabetes) 4.

Why Newer Agents Are Superior

The 2025 European Heart Journal guidelines and 2021 Mayo Clinic guidelines strongly favor patiromer or sodium zirconium cyclosilicate because they:

• Have no reported fatal adverse events in randomized trials 1
• Enable continuation and optimization of life-saving RAASi therapy 4, 1
• Have predictable onset (7 hours for patiromer, 1 hour for SZC) 1
• Are supported by robust placebo-controlled trials 1
• Reduce recurrent hyperkalaemia and associated cardiovascular events 4, 5

A 2023 editorial explicitly states that sodium polystyrene sulfonate "is unsafe and should not be prescribed" given the availability of safer alternatives 6.

Clinical Algorithm

For acute severe hyperkalaemia (K+ >6.5 mmol/L):

• Use emergency measures (insulin/glucose, calcium, salbutamol)
• Do NOT use calcium polystyrene sulphonate (delayed onset) 2
• Consider SZC if available (1-hour onset) 1

For chronic/recurrent hyperkalaemia:

1. First-line: Patiromer or SZC 4, 1
2. Only if newer agents unavailable AND no GI contraindications: calcium polystyrene sulphonate with intensive monitoring
3. Indefinite therapy likely needed for CKD/HF patients 4
4. Goal: Enable optimal RAASi dosing, not just potassium control 4, 1

Common Pitfalls

• Never co-administer with sorbitol (increases necrosis risk) 2
• Do not use in patients prone to aspiration or with impaired gag reflex 2
• Avoid in sodium-sensitive patients (heart failure, hypertension) if using sodium formulation - each 15g contains 1500mg sodium 1
• Do not heat the suspension (alters resin properties) 2
• Prepare fresh and use within 24 hours 2

The evidence overwhelmingly supports that calcium polystyrene sulphonate should be relegated to historical use only, replaced by patiromer or SZC which offer superior safety profiles and enable optimization of disease-modifying therapies that reduce cardiovascular mortality 4, 6.